Table 1. Summation of Differences in iTreg Pre-Clinical Results.

Differences in activation cue, polarizing cytokines, and infusion schedule have results in dramatically different results for iTreg therapy. Many more tests on GVL function are highly warranted.

Investigator	Activation Reagent	Polarizing Cytokines	Infusion Schedule	GVHD Outcome	GVL Outcome
Koenecke et al 2009	BM-derived mature DCs	IL-2 TGFβ RA	Tregs + Teff Day 0	No attenuation	Not tested
Beres et al 2011	Plate bound anti-CD3 Soluble anti-CD28	IL-2 TGFβ RA	Tregs + Teff Day 0	No attenuation	Not tested
Semple et al 2011	OVA peptide	IL-2 TGFβ RA	Tregs + Teff Day 0	Significant attenuation	Not tested
Sela et al 2011	CD11c+ DCs	IL-2 TGFβ RA	Tregs (multiple infusions) Teff Day 0	Significant attenuation	Not tested
Hippen et al 2011	KT64/86 With anti-CD3	IL-2 TGFβ Rapamycin	Tregs + Teff Day 0	Significant attenuation xenogeneic	Not tested
Zhang et al 2013	Plate bound anti-CD3 Soluble anti-CD28	IL-2 TGFβ Rapamycin	Tregs + Teff Day 0	Attenuation when stabilized by rapamycin/IL-2 complexes	Tregs impair CML clearance
Li et al 2015	HY peptide	IL-2 TGFβ RA	Tregs Day 0 Teff Day 3	Significant attenuation	Preserved GVL function
Heinrichs et al 2015	CD11c+ DCs	IL-2 IGFβ RA	Tregs Day 0 Teff Day 3	Significant attenuation	Tregs impair P815 clearence